Introduction
Kaposi (1894) first described the clinical and pathological features of "sarcoma idiopathic multiplex haemorrhagicum." Today the histological features and the clinical manifestations of Kaposi's sarcoma are still in the descriptive phase, and basic information regarding the possible aetiology, origin, and nature of the neoplastic cell, immunology, and response to therapy is scant.
The high incidence of Kaposi's sarcoma in Uganda provides a unique opportunity to investigate its clinical and pathological features. In a recent study of the clinical appearance and treatment of Kaposi's sarcoma in Uganda, Kyalwazi (1969) delineated two major types: "benign" and "malignant." Patients with the benign type present with a long history of subcutaneous nodules or raised hyperpigmented plaques on the extremities, often with oedema of the involved limb. Patients with the malignant type usually develop invasive deep ulcerating tumours or lymph node, visceral, and bone involvement. Some patients show a transition from the benign to the malignant type of lesion during their clinical course. This classification has been useful in the past in predicting the response to chemotherapy and the prognosis of the disease (Kyalwazi, 1968) .
Some clinical and histological features of Kaposi's sarcoma suggest that host immunity may influence the clinical manifestation and progression of the disease. The evidence for this hypothesis includes the indolent and benign nature of the clinical course in many cases (Kyalwazi, 1968) , the documented occurrence of spontaneous remissions (Lothe, 1963; Cook, 1966) , and the infiltration of the tumour by lymphocytes and plasma cells (Lothe, 1963; Slavin et al., 1969) . Accordingly, an evaluation of humoral and cellular immunological responses in Ugandan patients with Kaposi's sarcoma was performed.
Selection of Patients
The patients studied were admitted to the surgical wards of the New Mulago Hospital, Kampala, Uganda, between Sep- (Landy and Lamb, 1953 Immunoglobulin levels were performed by the gel-diffusion method (Fahey and McKelvey, 1965) Fig. 4 , all values falling within the normal range. Again no differences were observed between the benign and malignant groups.
The results of dinitrochlorobenzene testing are shown in the (Smith, 1968) , and Kaposi's sar--oma has been described as arising in a patient with immunosuppression following a homograft (Siegel et al., 1969) . On the other hand, some patients with advanced cancer may manifest depressed cellular immunity (Solowey et al., 1965) . Further studies will be necessary fully to elucidate the dynamic nature and extent of impairment of cellular immunity in malignant Kaposi's sarcoma and the relationship of immunological status to infectious complications, response to therapy, and the histopathology of the lesions. The finding of impaired delayed hypersensitivity in advanced Kaposi's sarcoma parallels the observations of the immune disorder in patients with Hodgkin's disease (Aisenberg, 1966; Brown, et al., 1967) . Both neoplasms have appeared concurrently in the same patient in much greater than chance association (Reynolds et al., 1965; O'Brien and Brasfield, 1966) . The exact pathogenetic and clinical relationships between Kaposi's sarcoma and Hodgkin's disease, however, remain speculative (Lancet, 1967) .
We are aware that the distinction between the benign and malignant types of Kaposi's sarcoma is based on clinical grounds alone. In a review of 70 patients seen at Mayo Clinic, Reynolds et al. (1965) pointed out the variations in the clinical appearance of the tumour, and attempted to correlate the gross lesion with the histological features. In a large series from Tanzania (Slavin et al., 1969) 
